In Vitro Pharmacology & Drug Screening Services
Comprehensive preclinical drug evaluation using physiologically relevant organoid models for accelerated drug discovery and development.
Advanced Drug Evaluation Services
The in vitro assessment of the efficacy of compounds to be tested against organoid models is a necessary step early in the development of antiviral drugs. Organoid models play an important role in high-throughput drug screening in large compound libraries, detection of single or multi-drug concentrations, rapid discovery of screened drugs, and timely evaluation and optimization of drug effects.
High-Throughput Screening
Rapid screening of large compound libraries using automated systems and standardized organoid models for efficient hit identification.
Dose-Response Analysis
Comprehensive evaluation of single and multi-drug concentrations to determine IC50, EC50, and therapeutic indices with precision.
Antiviral & Anticancer Testing
Specialized protocols for evaluating compound efficacy against viral infections and various cancer types using disease-relevant organoids.
Our Pharmacology Workflow
A systematic approach from compound testing to data analysis, ensuring reliable and reproducible results for your drug development pipeline.
Study Design
Custom protocol development based on compound properties, target indication, and regulatory requirements.
Model Selection
Choosing appropriate organoid models (normal vs. diseased, tissue-specific) for maximum physiological relevance.
Compound Testing
Systematic evaluation of compounds at various concentrations with appropriate controls and replicates.
Multi-Parametric Analysis
Comprehensive assessment using viability assays, imaging, molecular profiling, and functional readouts.
Data Interpretation
Statistical analysis, report generation, and expert interpretation of results with actionable insights.
Service Case Studies
Proven expertise in evaluating diverse therapeutic compounds across multiple disease areas.
Recent Evaluation Projects
- Evaluation of targeted drugs for drug-resistant lung cancer - Assessing novel TKIs and combination therapies
- ADC drug evaluation for breast cancer - Antibody-drug conjugate efficacy and safety profiling
- Colorectal Cancer Clinical Drug Evaluation - Testing standard-of-care and investigational agents
- Stomach Cancer Clinical Drug Evaluation - Gastric cancer organoid response to chemotherapy
- Ovarian Cancer Clinical Drug Evaluation - PARP inhibitors and platinum-based therapy testing
- Endometrial Cancer Clinical Drug Evaluation - Hormonal therapy and targeted agent assessment
- Pancreatic Cancer Clinical Drug Evaluation - Gemcitabine combinations and novel therapeutics
- Liver Cancer Clinical Drug Evaluation - Sorafenib and next-generation kinase inhibitors
Key Advantages
Rapid Turnaround
Accelerated screening timelines with results typically available in 2-4 weeks, speeding up your decision-making process.
Customizable Assays
Tailored endpoint measurements including viability, apoptosis, cell cycle, migration, invasion, and differentiation.
Regulatory-Ready Data
Comprehensive documentation, SOP adherence, and data packages suitable for regulatory submissions.
Ready to Evaluate Your Compounds?
Contact our pharmacology team to discuss your specific drug evaluation needs and get a customized study proposal.
Start Your Drug Screening Project